Published in Br J Haematol on May 19, 2011
Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One (2013) 0.82
Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med (2013) 0.80
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Ann Hematol (2012) 0.79
Organizing national responses for rare blood disorders: the Italian experience with sickle cell disease in childhood. Orphanet J Rare Dis (2013) 0.75
Safety of deferasirox in sickle cell disease patients with co-existing liver impairment. Br J Haematol (2012) 0.75
How we manage iron overload in sickle cell patients. Br J Haematol (2017) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
CDC growth charts: United States. Adv Data (2000) 38.32
Variations in pattern of pubertal changes in girls. Arch Dis Child (1969) 23.35
Variations in the pattern of pubertal changes in boys. Arch Dis Child (1970) 16.22
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am (1987) 7.63
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med (1998) 6.88
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Daily assessment of pain in adults with sickle cell disease. Ann Intern Med (2008) 3.81
Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med (2005) 3.38
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood (1999) 2.59
Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr (2001) 2.24
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood (2000) 1.84
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood (2007) 1.78
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Influence of sickle hemoglobinopathies on growth and development. N Engl J Med (1984) 1.76
Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol (1993) 1.76
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Classification and diagnosis of iron overload. Haematologica (1998) 1.45
Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol (2001) 1.42
Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload. Am J Hematol (2007) 1.39
Progression of iron overload in sickle cell disease. Semin Hematol (2001) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr Blood Cancer (2008) 1.14
Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin (2009) 1.11
Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr (2005) 1.04
Iron metabolism and iron chelation in sickle cell disease. Acta Haematol (2009) 1.00
Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy. J Pediatr Hematol Oncol (2009) 0.88
Consensus document for transfusion-related iron overload. Semin Hematol (2001) 0.83
Nontransferrin-bound iron in transfused patients with sickle cell disease. Int J Lab Hematol (2011) 0.83
Mechanisms and functional implications of adult neurogenesis. Cell (2008) 14.50
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA (2003) 8.18
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature (2005) 6.95
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Mili, a mammalian member of piwi family gene, is essential for spermatogenesis. Development (2004) 5.47
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
Successes and challenges of HIV prevention in men who have sex with men. Lancet (2012) 4.94
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis (2011) 4.72
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
The use of deception in public health behavioral intervention trials: a case study of three online alcohol trials. Am J Bioeth (2013) 4.37
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet (2008) 4.02
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med (2005) 3.26
NONCODE: an integrated knowledge database of non-coding RNAs. Nucleic Acids Res (2005) 3.16
Resolving new memories: a critical look at the dentate gyrus, adult neurogenesis, and pattern separation. Neuron (2011) 2.84
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Signaling in adult neurogenesis. Annu Rev Cell Dev Biol (2009) 2.47
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA (2010) 2.25
Factors associated with self-efficacy for condom use and sexual negotiation among South african youth. J Acquir Immune Defic Syndr (2006) 2.21
Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. Arch Gen Psychiatry (2010) 2.21
Indigenous peoples' health--why are they behind everyone, everywhere? Lancet (2005) 2.20
Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood (2010) 2.15
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2. Nat Genet (2011) 2.13
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med (2015) 2.03
Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene (2002) 2.03
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol (2006) 1.99
Social networking technologies as an emerging tool for HIV prevention: a cluster randomized trial. Ann Intern Med (2013) 1.97
Maternal cadmium exposure during pregnancy and size at birth: a prospective cohort study. Environ Health Perspect (2011) 1.94
Association of cerebral deficits with clinical symptoms in antipsychotic-naive first-episode schizophrenia: an optimized voxel-based morphometry and resting state functional connectivity study. Am J Psychiatry (2008) 1.86
Adult neurogenesis: integrating theories and separating functions. Trends Cogn Sci (2010) 1.83
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood (2002) 1.83
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
HIV-related stigma, social norms, and HIV testing in Soweto and Vulindlela, South Africa: National Institutes of Mental Health Project Accept (HPTN 043). J Acquir Immune Defic Syndr (2010) 1.78
Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. Hum Mol Genet (2011) 1.77
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Disappearing, displaced, and undervalued: a call to action for Indigenous health worldwide. Lancet (2006) 1.74
The relationship between online social networking and sexual risk behaviors among men who have sex with men (MSM). PLoS One (2013) 1.74
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood (2013) 1.68
An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis (2013) 1.67
GJB2 mutation spectrum in 2,063 Chinese patients with nonsyndromic hearing impairment. J Transl Med (2009) 1.66
Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet (2011) 1.60
Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS (2007) 1.60
Mutational spectrum in congenital dyserythropoietic anemia type II: identification of 19 novel variants in SEC23B gene. Am J Hematol (2010) 1.60
Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives. Am J Med Genet B Neuropsychiatr Genet (2007) 1.59
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood (2011) 1.58
Implementation and evaluation of an HIV/STD intervention in Peru. Eval Program Plann (2006) 1.55
Combined admixture mapping and association analysis identifies a novel blood pressure genetic locus on 5p13: contributions from the CARe consortium. Hum Mol Genet (2011) 1.54
Vulnerability and sexual risks: Vagos and vaguitas in a low income town in Perú. Cult Health Sex (2006) 1.53
Test and tell: correlates and consequences of testing and disclosure of HIV status in South Africa (HPTN 043 Project Accept). J Acquir Immune Defic Syndr (2009) 1.53
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol (2004) 1.51
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology (2011) 1.51
Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One (2011) 1.50
Efficacy and safety of traditional chinese medicine (Shenqi particle) for patients with idiopathic membranous nephropathy: a multicenter randomized controlled clinical trial. Am J Kidney Dis (2013) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Genome-wide association analysis with gray matter volume as a quantitative phenotype in first-episode treatment-naïve patients with schizophrenia. PLoS One (2013) 1.47
Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46
Mapping the C. elegans noncoding transcriptome with a whole-genome tiling microarray. Genome Res (2007) 1.46
Use of a high resolution melting (HRM) assay to compare gag, pol, and env diversity in adults with different stages of HIV infection. PLoS One (2011) 1.46
Assessing the incremental effects of combining economic and health interventions: the IMAGE study in South Africa. Bull World Health Organ (2009) 1.45
Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol (2008) 1.44
Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion (2013) 1.43
Should structural interventions be evaluated using RCTs? The case of HIV prevention. Soc Sci Med (2006) 1.43
Pregnancy and beta-thalassemia: an Italian multicenter experience. Haematologica (2009) 1.42
Global identification and characterization of transcriptionally active regions in the rice genome. PLoS One (2007) 1.41
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043). PLoS One (2013) 1.40
Land use/cover changes, the environment and water resources in northeast China. Environ Manage (2005) 1.40
Paucity of education regarding pacemakers/cardiovascular implantable electronic devices in anesthesiology training programs is a patient safety hazard. Anesth Analg (2013) 1.39
Interaction of sickle cell trait with hereditary spherocytosis: splenic infarcts and sequestration. Acta Haematol (2003) 1.39
Spatial distribution of inorganic nitrogen contents of marsh soils in a river floodplain with different flood frequencies from soil-defrozen period. Environ Monit Assess (2007) 1.39
Primary Epstein-Barr virus infection with pneumonia transmitted by allogeneic bone marrow after transplantation. Clin Infect Dis (2006) 1.39
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood (2011) 1.37
Prediction of structured non-coding RNAs in the genomes of the nematodes Caenorhabditis elegans and Caenorhabditis briggsae. J Exp Zool B Mol Dev Evol (2006) 1.34